Cure My Disease

Don't miss your cure!

 Log in / Sign up

New radioactive compound shows promise in first human tests for advanced cancer

NCT ID NCT07299253

Disease control Sponsor: Lanzhou University Second Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a new radioactive drug called [177Lu]Lu-TEFAPI-06 in 5 people with advanced solid tumors that had spread and were no longer responding to standard treatments. The main goal was to check safety and see how the drug moves through the body. Researchers also looked at whether it could help control the disease by targeting a protein found in many cancers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

5 people

The number who actually took part.

Started

Aug 2023

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \> 18 years * Histologically confirmed advanced metastatic solid tumors refractory or intolerant to standard therapies * ECOG performance status 0-2 * Life expectancy \> 3 months * At least one FAP-avid lesion confirmed by baseline \[18F\]-FAPI PET/CT * Adequate organ and bone marrow function prior to the first dose Exclusion Criteria: * Chemotherapy, radiotherapy, or targeted therapy within 4 weeks * Severe hepatic or renal dysfunction * Uncontrolled active infection or severe comorbidities

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic solid tumors (any localization) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic solid tumors (any localization)

Contacts and locations

Locations

  • The Second Hospital & Clinical Medical School, Lanzhou University

    Lanzhou, Gansu, 730000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.